Veritable’s NextCure NXTC Stock Holding History

Veritable’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,067	Closed	-$179K	–	946
2022 Q1	$179K	Hold	3,067	–	–	﹤0.01%	870
2021 Q4	$221K	Hold	3,067	–	–	﹤0.01%	848
2021 Q3	$248K	Hold	3,067	–	–	﹤0.01%	764
2021 Q2	$296K	Buy	+3,067	New	+$314K	﹤0.01%	695

Other funds holding NXTC

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Veritable's NXTC Position: Q2 2022 in Review

Veritable sold out of NextCure (NXTC) in Q2 2022, closing a stake of 3,067 shares — an estimated $179K sold.

Veritable first reported a position in NXTC in Q2 2021 and held it in 4 quarters. The position peaked at $296K in Q2 2021. 51 funds tracked by Wall St. Rank hold NXTC as of Q2 2022.

Veritable reported no remaining NextCure position as of Q2 2022 after selling out during the quarter.
Veritable sold 3,067 NextCure shares in Q2 2022, an estimated $179K.
Veritable first reported a position in NextCure in Q2 2021 and held it in 4 quarters.
Veritable's NextCure position peaked at $296K in Q2 2021.
51 funds tracked by Wall St. Rank held NextCure as of Q2 2022.

Based on Veritable's 13F filing for Q2 2022, filed 15 Aug 2022.